November 16, 2023
QLSF will present prelinical data of two new clinical stage programs at the AACR Annual Meeting 2024 in San Diego.
Poster presentations will include QL325, a novel T cell engager targeting CLEC12A for acute myeloid leukemia, and QL335, a novel T cell engager targeting LY6G6D for colorectal cancer. Both programs are currently in Phase 1 trial.
October 10, 2023
QLSF announces first patient dosed in a Phase 1 trial of QL335, a novel T cell engager targeting LY6G6D for colorectal cancer.
March 1, 2023
QLSF announces first patient dosed in a Phase 1 trial of QL325, a novel T cell engager targeting CLEC12A for acute myeloid leukemia.
November 20, 2021
QLSF Biotherapeutics to present preclinical data of 3 clinical stage programs at the AACR Annual Meeting 2022 in New Orleans.
Poster presentations will feature QL301 PD-L1 x 4-1BB bispecific antibody, QL401 PD-L1 x 4-1BB bispecific antibody, and QL415 PD-L1 IL-15 cytokine fusion protein.
November 2, 2021
First patient dosed in a Phase 1 study of QL415 PD-L1 x IL-15 cytokine fusion protein
The phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QL415 as a monotherapy in patient with advanced malignant tumors.
October 21, 2021
First patient dosed in a Phase 1 study of QL301 PD-L1 x 4-1BB bispecific antibody
The phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QL301 as a monotherapy in patient with advanced malignant tumors.
